FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

Data Compilation
#PharmaFlow

Pipeline Prospector 2025 highlights: FDA approves pill version of Novo’s Wegovy; BioMarin acquires Amicus for US$ 4.8 bn

Stock Recap
#PipelineProspector

Atazanavir Sulfate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 24 USDMF, 7 CEP/COS, 10 EU WC, 1 KDMF, 15 NDC API, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

76 FDF Dossiers, 42 FDA Orange Book, 15 Europe, 11 Canada, 2 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 8 DKSH, 5 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

34 Fillers, Diluents & Binders, 22 Disintegrants & Superdisintegrants, 21 Thickeners and Stabilizers, 18 Granulation, 16 Lubricants & Glidants, 15 Direct Compression, 13 Coating Systems & Additives, 8 Co-Processed Excipients, 8 Film Formers & Plasticizers, 8 Empty Capsules, 8 Emulsifying Agents, 7 Taste Masking, 7 Topical, 4 Parenteral, 4 Solubilizers, 4 Controlled & Modified Release, 4 Chewable & Orodispersible Aids, 3 Surfactant & Foaming Agents, 3 Coloring Agents, 2 Rheology Modifiers, 1 API Stability Enhancers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 10 News #PharmaBuzz

GLOBAL SALES INFORMATION

9 US Medicaid Prescriptions, 5 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
30/12/2025	SK Biotek	U.S.A	Korea BMS Pharmaceutical Co., Ltd.	Su335-4-ND	Atazanavir sulfate	2009-08-21	SK Biotek Ireland Limited	Ireland	Watery Lane, Swords, County Dublin
19/01/2026	Korea BMS Pharmaceutical Co., Ltd.	Gabon	Korea BMS Pharmaceutical Co., Ltd.	Su342-15-ND	Atazanavir Sulfate	2021-03-16	Siegfried St. Vulbas SAS	France	Parc Industriel de la Plaine de I`Ain 530 Allee de la Luye 01150 SAINT-VULBAS, France

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Atazanavir Sulfate

Atazanavir Sulfate

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers

24 USDMF

7 CEP/COS

10 EU WC

1 KDMF

15 NDC API

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

76 FDF Dossiers

42 FDA Orange Book

15 Europe

11 Canada

2 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG

CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 200MG BASE

CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

1 SPI Pharma

8 DKSH

5 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Pfanstiehl

2 Kirsch Pharma

4 ACG Worldwide

1 Actylis

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 BASF

6 DFE Pharma

1 Finar

6 Gangwal Chemicals

1 Ideal Cures

2 Ingredion Pharma Solutions

10 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

2 Nitika Pharmaceutical Specialities

2 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qualicaps

14 Roquette

3 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

4 Silverline Chemicals

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

34 Fillers, Diluents & Binders

22 Disintegrants & Superdisintegrants

21 Thickeners and Stabilizers

18 Granulation

16 Lubricants & Glidants

15 Direct Compression

13 Coating Systems & Additives

8 Co-Processed Excipients

8 Film Formers & Plasticizers

8 Empty Capsules

8 Emulsifying Agents

7 Taste Masking

7 Topical

4 Parenteral

4 Solubilizers

4 Controlled & Modified Release

4 Chewable & Orodispersible Aids

CAPSULE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons